Probiotics and gastrointestinal disease: Clinical evidence and basic science

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2009, Pages 260-269

  Petrof, Elaine O ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Colitis; Inflammation; Intestinal microbiota; Probiotics

Indexed keywords

MESALAZINE; PLACEBO; PROBIOTIC AGENT; VANCOMYCIN;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; ILEITIS; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MICROBIAL ACTIVITY; NONHUMAN; REVIEW; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS;

EID: 73549103855     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309789151977     Document Type: Review

References (98)

1. Ley, R. E.; Peterson, D. A.; Gordon, J. I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell, 2006, 124(4), 837-848.
2. Hooper, L. V.; Midtvedt, T.; Gordon, J. I. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu. Rev. Nutr., 2002, 22, 283-307.
3. Backhed, F.; Ley, R. E.; Sonnenburg, J. L.; Peterson, D. A.; Gordon, J. I. Host-bacterial mutualism in the human intestine. Science, 2005, 307(5717), 1915-1920.
4. Christensen, H. R.; Frokiaer, H.; Pestka, J. J. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J. Immunol., 2002, 168(1), 171-178.
5. Stecher, B.; Hardt, W. D. The role of microbiota in infectious disease. Trends Microbiol., 2008, 16(3), 107-114.
6. Riley, M. A.; Wertz, J. E. Bacteriocins: evolution, ecology, and application. Annu. Rev. Microbiol., 2002, 56, 117-137.
7. Corr, S. C.; Li, Y.; Riedel, C. U.; O'Toole, P. W.; Hill, C.; Gahan, C. G. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. USA, 2007, 104(18), 7617-7621.
8. Hamilton-Miller, J. M.; Shah, S. Deficiencies in microbiological quality and labelling of probiotic supplements. Int. J. Food Microbiol., 2002, 72(1-2), 175-176.
9. Hibberd, P. L.; Davidson, L. Probiotic foods and drugs: impact of US regulatory status on design of clinical trials. Clin. Infect. Dis., 2008, 46(Suppl 2), S137-140; discussion S144-51.
10. Hoffman, F. A.; Heimbach, J. T.; Sanders, M. E.; Hibberd, P. L. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin. Infect. Dis., 2008, 46(Suppl 2), S53-57.
11. Reid, G. The importance of guidelines in the development and application of probiotics. Curr. Pharm. Des., 2005, 11(1), 11-16.
12. Rioux, K. P.; Madsen, K. L.; Fedorak, R. N., The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol. Clin. North Am., 2005, 34(3), 465-482, ix.
13. Reid, G.; Jass, J.; Sebulsky, M. T.; McCormick, J. K. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev., 2003, 16(4), 658-672.
14. Sartor, R. B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology, 2004, 126(6), 1620-1633.
15. Venturi, A.; Gionchetti, P.; Rizzello, F.; Johansson, R.; Zucconi, E.; Brigidi, P.; Matteuzzi, D.; Campieri, M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther., 1999, 13(8), 1103-1108.
16. Gionchetti, P.; Rizzello, F.; Venturi, A.; Brigidi, P.; Matteuzzi, D.; Bazzocchi, G.; Poggioli, G.; Miglioli, M.; Campieri, M., Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 2000, 119(2), 305-309.
17. Mimura, T.; Rizzello, F.; Helwig, U.; Poggioli, G.; Schreiber, S.; Talbot, I. C.; Nicholls, R. J.; Gionchetti, P.; Campieri, M.; Kamm, M. A. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004, 53(1), 108-114.
18. Gionchetti, P.; Rizzello, F.; Helwig, U.; Venturi, A.; Lammers, K. M.; Brigidi, P.; Vitali, B.; Poggioli, G.; Miglioli, M.; Campieri, M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124(5), 1202-1209.
19. Bibiloni, R.; Fedorak, R. N.; Tannock, G. W.; Madsen, K. L.; Gionchetti, P.; Campieri, M.; De Simone, C.; Sartor, R. B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol., 2005, 100(7), 1539-1546.
20. Madsen, K.; Cornish, A.; Soper, P.; McKaigney, C.; Jijon, H.; Yachimec, C.; Doyle, J.; Jewell, L.; De Simone, C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology, 2001, 121(3), 580-591.
21. Otte, J. M.; Podolsky, D. K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286(4), G613-626.
22. Petrof, E. O.; Kojima, K.; Ropeleski, M. J.; Musch, M. W.; Tao, Y.; De Simone, C.; Chang, E. B. Probiotics inhibit nuclear factorkappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology, 2004, 127(5), 1474-1487.
23. Jijon, H.; Backer, J.; Diaz, H.; Yeung, H.; Thiel, D.; McKaigney, C.; De Simone, C.; Madsen, K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology, 2004, 126(5), 1358-1373.
24. Rachmilewitz, D.; Katakura, K.; Karmeli, F.; Hayashi, T.; Reinus, C.; Rudensky, B.; Akira, S.; Takeda, K.; Lee, J.; Takabayashi, K.; Raz, E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology, 2004, 126(2), 520-528.
25. Nissle, A. Mutaflor and its medical significance. Z Klin Med., 1951, 2(3-4), 68.
26. Schultz, M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm. Bowel Dis., 2008, 14(7), 1012-1018.
27. Kruis, W.; Fric, P.; Pokrotnieks, J.; Lukas, M.; Fixa, B.; Kascak, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.; Schulze, J., Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53(11), 1617-1623.
28. Kruis, W.; Schutz, E.; Fric, P.; Fixa, B.; Judmaier, G.; Stolte, M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 1997, 11(5), 853-858.
29. Rembacken, B. J.; Snelling, A. M.; Hawkey, P. M.; Chalmers, D. M.; Axon, A. T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet, 1999, 354(9179), 635-639.
30. Kamada, N.; Inoue, N.; Hisamatsu, T.; Okamoto, S.; Matsuoka, K.; Sato, T.; Chinen, H.; Hong, K. S.; Yamada, T.; Suzuki, Y.; Suzuki, T.; Watanabe, N.; Tsuchimoto, K.; Hibi, T. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm. Bowel Dis., 2005, 11(5), 455-463.
31. Grabig, A.; Paclik, D.; Guzy, C.; Dankof, A.; Baumgart, D. C.; Erckenbrecht, J.; Raupach, B.; Sonnenborn, U.; Eckert, J.; Schumann, R. R.; Wiedenmann, B.; Dignass, A. U.; Sturm, A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect. Immun., 2006, 74(7), 4075-4082.
32. Schultz, M.; Strauch, U. G.; Linde, H. J.; Watzl, S.; Obermeier, F.; Gottl, C.; Dunger, N.; Grunwald, N.; Scholmerich, J.; Rath, H. C. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin. Diagn. Lab Immunol., 2004, 11(2), 372-378.
33. Kamada, N.; Maeda, K.; Inoue, N.; Hisamatsu, T.; Okamoto, S.; Hong, K. S.; Yamada, T.; Watanabe, N.; Tsuchimoto, K.; Ogata, H.; Hibi, T. Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect. Immun., 2008, 76(1), 214-220.
34. Zyrek, A. A.; Cichon, C.; Helms, S.; Enders, C.; Sonnenborn, U.; Schmidt, M. A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol., 2007, 9(3), 804-816.
35. Wehkamp, J.; Harder, J.; Wehkamp, K.; Wehkamp-von Meissner, B.; Schlee, M.; Enders, C.; Sonnenborn, U.; Nuding, S.; Bengmark, S.; Fellermann, K.; Schroder, J. M.; Stange, E. F. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun., 2004, 72(10), 5750-5758.
36. Schlee, M.; Wehkamp, J.; Altenhoefer, A.; Oelschlaeger, T. A.; Stange, E. F.; Fellermann, K., Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun., 2007, 75(5), 2399-2407.
37. Ramasundara, M.; Leach, S. T.; Lemberg, D. A.; Day, A. S. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol., 2009, 24(2), 202-208.
38. Walter, J. Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. Appl. Environ. Microbiol., 2008, 74(16), 4985-4996.
39. Conway, P. L.; Gorbach, S. L.; Goldin, B. R. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J. Dairy Sci., 1987, 70(1), 1-12.
40. Goldin, B. R.; Gorbach, S. L.; Saxelin, M.; Barakat, S.; Gualtieri, L.; Salminen, S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig. Dis. Sci., 1992, 37(1), 121-128.
41. Saxelin, M.; Pessi, T.; Salminen, S. Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers. Int. J. Food Microbiol., 1995, 25(2), 199-203.
42. Vanderhoof, J. A.; Whitney, D. B.; Antonson, D. L.; Hanner, T. L.; Lupo, J. V.; Young, R. J. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J. Pediatr., 1999, 135(5), 564-568.
43. Szajewska, H.; Kotowska, M.; Mrukowicz, J. Z.; Armanska, M.; Mikolajczyk, W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr., 2001, 138(3), 361-365.
44. Majamaa, H.; Isolauri, E.; Saxelin, M.; Vesikari, T., Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediatr. Gastroenterol. Nutr., 1995, 20(3), 333-338.
45. Guandalini, S.; Pensabene, L.; Zikri, M. A.; Dias, J. A.; Casali, L. G.; Hoekstra, H.; Kolacek, S.; Massar, K.; Micetic-Turk, D.; Papadopoulou, A.; de Sousa, J. S.; Sandhu, B.; Szajewska, H.; Weizman, Z. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J. Pediatr. Gastroenterol. Nutr., 2000, 30(1), 54-60.
46. Isolauri, E.; Juntunen, M.; Rautanen, T.; Sillanaukee, P.; Koivula, T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics, 1991, 88(1), 90-97.
47. Arvola, T.; Laiho, K.; Torkkeli, S.; Mykkanen, H.; Salminen, S.; Maunula, L.; Isolauri, E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics, 1999, 104, (5), e64.
48. Kalliomaki, M.; Salminen, S.; Poussa, T.; Arvilommi, H.; Isolauri, E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet, 2003, 361(9372), 1869-1871.
49. Ellison, R. T. 3rd, Review: probiotics are effective for prevention of antibiotic-associated diarrhea and treatment of Clostridium difficile disease. ACP J. Club., 2006, 145(2), 46.
50. McFarland, L. V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol., 2006, 101(4), 812-822.
51. D'Souza, A. L.; Rajkumar, C.; Cooke, J.; Bulpitt, C. J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ, 2002, 324(7350), 1361.
52. Szajewska, H.; Setty, M.; Mrukowicz, J.; Guandalini, S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J. Pediatr. Gastroenterol. Nutr., 2006, 42(5), 454-475.
53. Doron, S. I.; Hibberd, P. L.; Gorbach, S. L. Probiotics for prevention of antibiotic-associated diarrhea. J. Clin. Gastroenterol., 2008, 42(Suppl 2), S58-63.
54. Floch, M. H.; Walker, W. A.; Guandalini, S.; Hibberd, P.; Gorbach, S.; Surawicz, C.; Sanders, M. E.; Garcia-Tsao, G.; Quigley, E. M.; Isolauri, E.; Fedorak, R. N.; Dieleman, L. A. Recommendations for probiotic use--2008. J. Clin. Gastroenterol., 2008, 42(Suppl 2), S104-108.
55. Silva, M.; Jacobus, N. V.; Deneke, C.; Gorbach, S. L. Antimicrobial substance from a human Lactobacillus strain. Antimicrob. Agents Chemother., 1987, 31(8), 1231-1233.
56. Gupta, P.; Andrew, H.; Kirschner, B. S.; Guandalini, S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr., 2000, 31(4), 453-457.
57. Isolauri, E.; Majamaa, H.; Arvola, T.; Rantala, I.; Virtanen, E.; Arvilommi, H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology, 1993, 105(6), 1643-1650.
58. Johnson-Henry, K. C.; Donato, K. A.; Shen-Tu, G.; Gordanpour, M.; Sherman, P. M. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect. Immun., 2008, 76(4), 1340-1348.
59. Tao, Y.; Drabik, K. A.; Waypa, T. S.; Musch, M. W.; Alverdy, J. C.; Schneewind, O.; Chang, E. B.; Petrof, E. O. Soluble factors from the probiotic Lactobacillus GG activate MAP kinases and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am. J. Physiol. Cell Physiol., 2005, 290(4):C1018-1030.
60. Musch, M. W.; Sugi, K.; Straus, D.; Chang, E. B. Heat-shock protein 72 protects against oxidant-induced injury of barrier function of human colonic epithelial Caco2/bbe cells. Gastroenterology, 1999, 117(1), 115-122.
61. Seth, A.; Yan, F.; Polk, D. B.; Rao, R. K. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294(4), G1060-1069.
62. Yan, F.; Polk, D. B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem., 2002, 277(52), 50959-50965.
63. Lan, P. T.; Hayashi, H.; Sakamoto, M.; Benno, Y. Phylogenetic analysis of cecal microbiota in chicken by the use of 16S rDNA clone libraries. Microbiol. Immunol., 2002, 46(6), 371-382.
64. Naito, S.; Hayashidani, H.; Kaneko, K.; Ogawa, M.; Benno, Y. Development of intestinal lactobacilli in normal piglets. J. Appl. Bacteriol., 1995, 79(2), 230-236.
65. Molin, G.; Johansson, M. L.; Stahl, M.; Ahrne, S.; Andersson, R.; Jeppsson, B.; Bengmark, S. Systematics of the Lactobacillus population on rat intestinal mucosa with special reference to Lactobacillus reuteri. Antonie Van Leeuwenhoek, 1992, 61(3), 175-183.
66. Shornikova, A. V.; Casas, I. A.; Isolauri, E.; Mykkanen, H.; Vesikari, T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J. Pediatr. Gastroenterol. Nutr., 1997, 24(4), 399-404.
67. Shornikova, A. V.; Casas, I. A.; Mykkanen, H.; Salo, E.; Vesikari, T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr. Infect. Dis. J., 1997, 16(12), 1103-1107.
68. Madsen, K. L.; Doyle, J. S.; Jewell, L. D.; Tavernini, M. M.; Fedorak, R. N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology, 1999, 116(5), 1107-1114.
69. Petrof, E. O.; Claud, E. C.; Sun, J.; Abramova, T.; Guo, Y.; Waypa, T. S.; He, S. M.; Nakagawa, Y.; Chang, E. B. Bacteria-free solution derived from lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function. Inflamm. Bowel Dis., 2009 (in press).
70. Lin, Y. P.; Thibodeaux, C. H.; Pena, J. A.; Ferry, G. D.; Versalovic, J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm. Bowel Dis., 2008, 14(8), 1068-1083.
71. Iyer, C.; Kosters, A.; Sethi, G.; Kunnumakkara, A. B.; Aggarwal, B. B.; Versalovic, J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol., 2008, 10(7), 1442-1452.
72. Spinler, J. K.; Taweechotipatr, M.; Rognerud, C. L.; Ou, C. N.; Tumwasorn, S.; Versalovic, J. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe, 2008, 14(3), 166-171.
73. Surawicz, C. M. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract. Res. Clin. Gastroenterol., 2003, 17(5), 775-783.
74. Blehaut, H.; Massot, J.; Elmer, G. W.; Levy, R. H. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm. Drug Dispos., 1989, 10(4), 353-364.
75. Bleichner, G.; Blehaut, H.; Mentec, H.; Moyse, D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients: a multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med., 1997, 23(5), 517-523.
76. Czerucka, D.; Dahan, S.; Mograbi, B.; Rossi, B.; Rampal, P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect. Immun., 2000, 68(10), 5998-6004.
77. Dahan, S.; Dalmasso, G.; Imbert, V.; Peyron, J. F.; Rampal, P.; Czerucka, D. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect. Immun., 2003, 71(2), 766-773.
78. Kimmey, M. B.; Elmer, G. W.; Surawicz, C. M.; McFarland, L. V., Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig. Dis. Sci., 1990, 35(7), 897-901.
79. McFarland, L. V.; Surawicz, C. M.; Greenberg, R. N.; Elmer, G. W.; Moyer, K. A.; Melcher, S. A.; Bowen, K. E.; Cox, J. L. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am. J. Gastroenterol., 1995, 90(3), 439-448.
80. McFarland, L. V.; Surawicz, C. M.; Greenberg, R. N.; Fekety, R.; Elmer, G. W.; Moyer, K. A.; Melcher, S. A.; Bowen, K. E.; Cox, J. L.; Noorani, Z. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA, 1994, 271(24), 1913-1918.
81. Surawicz, C. M.; Elmer, G. W.; Speelman, P.; McFarland, L. V.; Chinn, J.; van Belle, G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology, 1989, 96(4), 981-988.
82. Surawicz, C. M.; McFarland, L. V.; Greenberg, R. N.; Rubin, M.; Fekety, R.; Mulligan, M. E.; Garcia, R. J.; Brandmarker, S.; Bowen, K.; Borjal, D.; Elmer, G. W. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis., 2000, 31(4), 1012-1017.
83. Bartlett, J. G.; Gerding, D. N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis., 2008, 46(Suppl 1), S12-18.
84. Surawicz, C. M. Treatment of recurrent Clostridium difficile-associated disease. Nat .Clin. Pract. Gastroenterol. Hepatol., 2004, 1(1), 32-38.
85. Cassone, M.; Serra, P.; Mondello, F.; Girolamo, A.; Scafetti, S.; Pistella, E.; Venditti, M. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J. Clin. Microbiol., 2003, 41(11), 5340-5343.
86. Munoz, P.; Bouza, E.; Cuenca-Estrella, M.; Eiros, J. M.; Perez, M. J.; Sanchez-Somolinos, M.; Rincon, C.; Hortal, J.; Pelaez, T. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin. Infect. Dis., 2005, 40(11), 1625-1634.
87. Herbrecht, R.; Nivoix, Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin. Infect. Dis., 2005, 40(11), 1635-1637.
88. Castagliuolo, I.; LaMont, J. T.; Nikulasson, S. T.; Pothoulakis, C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect. Immun., 1996, 64(12), 5225-5232.
89. Castagliuolo, I.; Riegler, M. F.; Valenick, L.; LaMont, J. T.; Pothoulakis, C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect. Immun., 1999, 67(1), 302-307.
90. Buts, J. P.; Bernasconi, P.; Vaerman, J. P.; Dive, C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig. Dis. Sci., 1990, 35(2), 251-256.
91. Qamar, A.; Aboudola, S.; Warny, M.; Michetti, P.; Pothoulakis, C.; LaMont, J. T.; Kelly, C. P. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect. Immun., 2001, 69(4), 2762-2765.
92. Johnson, S.; Sypura, W. D.; Gerding, D. N.; Ewing, S. L.; Janoff, E. N. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun., 1995, 63(8), 3166-3173.
93. Rautio, M.; Jousimies-Somer, H.; Kauma, H.; Pietarinen, I.; Saxelin, M.; Tynkkynen, S.; Koskela, M. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin. Infect. Dis., 1999, 28(5), 1159-1160.
94. Borriello, S. P.; Hammes, W. P.; Holzapfel, W.; Marteau, P.; Schrezenmeir, J.; Vaara, M.; Valtonen, V. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin. Infect. Dis., 2003, 36(6), 775-780.
95. Besselink, M. G.; van Santvoort, H. C.; Buskens, E.; Boermeester, M. A.; van Goor, H.; Timmerman, H. M.; Nieuwenhuijs, V. B.; Bollen, T. L.; van Ramshorst, B.; Witteman, B. J.; Rosman, C.; Ploeg, R. J.; Brink, M. A.; Schaapherder, A. F.; Dejong, C. H.; Wahab, P. J.; van Laarhoven, C. J.; van der Harst, E.; van Eijck, C. H.; Cuesta, M. A.; Akkermans, L. M.; Gooszen, H. G. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet, 2008, 371(9613), 651-659.
96. Temmerman, R.; Pot, B.; Huys, G.; Swings, J. Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int. J. Food Microbiol., 2003, 81(1), 1-10.
97. Tannock, G. W. Exploring the relationships between intestinal microflora and inflammatory conditions of the human bowel and spine. Antonie Van Leeuwenhoek, 2002, 81(1-4), 529-535.
98. Tannock, G. W. The search for disease-associated compositional shifts in bowel bacterial communities of humans. Trends Microbiol., 2008, 16(10), 488-495.